Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic heterogeneity may be present in both genes. We collected 179 pedigrees with identified germline mutation (104 BRCA1 and 75 BRCA2), ascertained in six collaborating centers of the Italian Consortium for Hereditary Breast and Ovarian Cancer. Significant heterogeneity was detected for several variables, and a logistic regression model including age of diagnosis in the proband, presence of ovarian cancer in the family, presence of prostate or pancreatic cancer in the family, and presence of male breast cancer in the family proved to be effective in predicting the presence of a mutation in a gene rather than the other. Excess of familial aggregation...
PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and...
BACKGROUND.Factors that are predictive of carrying BRCA1 and BRCA2 germline mutations in patients wi...
Pathogenic variants (PVs) carriers in BRCA1 or BRCA2 are associated with an elevated lifetime risk o...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
The heritable defects of BRCA1 and BRCA2 genes have been shown to predispose to breast and ovarian c...
Germline point mutations in BRCA1 and BRCA2 genes account for about 30% of the inherited breast and ...
BACKGROUND: Breast cancer is an extremely complex disease, characterized by a progressive multist...
Double heterozygosity (DH) in BRCA1 and BRCA2 genes and double mutation (DM) in BRCA1 or BRCA2 are e...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
Genetic linkage studies have led to the identification of highly penetrant genes as the possible cau...
BACKGROUND: Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-on...
PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and...
BACKGROUND.Factors that are predictive of carrying BRCA1 and BRCA2 germline mutations in patients wi...
Pathogenic variants (PVs) carriers in BRCA1 or BRCA2 are associated with an elevated lifetime risk o...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic he...
The heritable defects of BRCA1 and BRCA2 genes have been shown to predispose to breast and ovarian c...
Germline point mutations in BRCA1 and BRCA2 genes account for about 30% of the inherited breast and ...
BACKGROUND: Breast cancer is an extremely complex disease, characterized by a progressive multist...
Double heterozygosity (DH) in BRCA1 and BRCA2 genes and double mutation (DM) in BRCA1 or BRCA2 are e...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer. Mutational hot...
Genetic linkage studies have led to the identification of highly penetrant genes as the possible cau...
BACKGROUND: Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-on...
PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and...
BACKGROUND.Factors that are predictive of carrying BRCA1 and BRCA2 germline mutations in patients wi...
Pathogenic variants (PVs) carriers in BRCA1 or BRCA2 are associated with an elevated lifetime risk o...